

PATENT
Attorney Docket No.: 015270-01430US
Client Ref. No.: 120-ICT-CIP1

#13/B
ghd
3/22/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Elan Pharmaceuticals

Application No.: 09/155,739

Filed: September 11, 1998

For: THERAPEUTIC USES OF
HUMANIZED ANTIBODIES AGAINST
ALPHA-4 INTEGRIN

Examiner: Philip Gambel, Ph.D.

Art Unit: 1644

**AMENDMENT AND RESPONSE TO
SPECIES ELECTION**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Communication mailed May 17, 2001, please enter and consider the following. A four-month extension of time is submitted herewith as a separate paper.

IN THE SPECIFICATION:

Please replace the heading and paragraph beginning at page 1, line 7 with the following amended paragraph:

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of USSN 08/561,521, filed November 21, 1995, which issued as U.S. Patent No. 5,840,299 on November 24, 1998, which is incorporated by reference in their entirety for all purposes.—

B11NS
C1